Evaluation of 2-(methylaminosulfonyl)-1-(arylsulfonyl)hydrazines as anticancer agents

Neoplasma

Volumn 46, Issue 4, 1999, Pages 242-245

  Ghosh, M ^a   Dutta, S ^a   Sanyal, U ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Ehrlich ascites carcinoma; Human tumor lines; Mice; New anticancer agents; Screening

Indexed keywords

1,2 BIS(SULFONYL) 1 METHYLHYDRAZINE; 4 (4 NITROBENZYL)PYRIDINE; HYDRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; NONHUMAN;

EID: 0032823329     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. BHATTACHARYA, S., GHOSH, M., SADHU, U., DUTTA, S., SANYAL, U.: Evaluation of phthalmustine, a new anticancer compound. II. Tumor inhibitory effect in murine Ehrlich ascites carcinoma and sarcoma-180. Neoplasma, 43, 1996, 209-213.
2. BOYD, M.R.: Status of the NCI preclinical antitumor drug delivery screen. Principl. Pract. Oncol., 3, 1989, 1-12.
3. CREMLYN, R.J.W.: Sulfonylhydrazides and related compounds. Part VI. Some halogeno and nitrobenzenesulphonhydrazides. J. Chem. Soc., C., 1966, 1229-1232.
4. DZHIDZHELAVA, A.B., KONOLOVA, M.YA., KOSTENKO, V.I., DYKHANOV, N.N.: Organic electrets. Hydrazides of aromatic sulfonic acids. Zh. Obshch. Khim., 35, 1965, 831-833. (In Russian.)
5. GERAN, R.I., GREENBERG, N.H., MACDONALD, M.M., SCHUMACHER, A.M., ABBOTT, B.J.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., Part 3, 3, 1972, 1-103.
6. GHOSH, M., BHATTACHARYA, S., SADHU, U., DUTTA, S., SANYAL, U.: Evaluation of β-tethymustine, a new anticancer compound, in murine tumor models. Cancer Lett., 119, 1997, 7-12.
7. HOWARTH, N.M., PUROHIT, A., REED, M.J., POTTER, B.V.L.: Estrone sulfamates: Potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem., 37, 1994, 219-221.
8. SANYAL, U., DE (BISWAS), R., DUTTA, S., DAS, H., GHOSH, M.: Evaluation of 2-(methylaminosulfonyl)-l-(arylsulfonyl)-l-methylhydrazines as anticancer agents. Neoplasma, 40, 1993, 219-222.
9. SHYAM, K., COSBY L.A., SARTORELLI, A.C.: Synthesis and evaluation of N,N'-bis(arylsulfonyl)hydrazines as antineoplastic agents. J. Med. Chem., 28, 1985, 525-527.
10. SHYAM, K., HRUBIEC, R.T., FURUBAYASHI, R., COSBY, L.A., SARTORELLI, A.C.: 1,2-bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity. J. Med. Chem., 30, 1987, 2157-2161 and the references cited therein.
11. WEIS, V.G., SCHULZE, G.: Herstellung und Reaktionen von N-monoalkylamidosulfonylchloriden. Liebigs Ann. Chem., 729, 1969, 40-51.
12. WHEELER, G.P., CHUMLEY, S.: Alkylating activity of 1,3-bis(2-chloroethyl)-I-nitrosourea and related compounds. J. Med. Chem., 10, 1967, 259-261.
13. Woo, L.W.L., PUROHIT, A, REED, M.J., POTTER, B.V.L.: Active site inhibition of estrone sulfatase by non-steroidal coumarin sulfamates. J. Med. Chem., 39, 1996, 1349-1351.